Clinical Trials Logo

Sexually Transmitted Diseases clinical trials

View clinical trials related to Sexually Transmitted Diseases.

Filter by:

NCT ID: NCT05630859 Active, not recruiting - Clinical trials for Sexually Transmitted Diseases

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.

Start date: November 28, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this first time in human proof of concept (FTiH-PoC) study is to evaluate safety and reactogenicity, to demonstrate efficacy and to explore immunogenicity of GlaxoSmithKline's (GSK) Neisseria gonorrhoeae generalized modules for membrane antigens (GMMA) (NgG) investigational vaccine compared to placebo (saline).

NCT ID: NCT05619497 Recruiting - Clinical trials for Human Immunodeficiency Virus

The OPENS Trial: Offering Women PrEP (Aim 2)

Start date: December 2, 2022
Phase: N/A
Study type: Interventional

To address the significant barriers to pre-exposure prophylaxis (PrEP) implementation for cisgender women and address racial inequities in HIV prevention in the United States (US), a novel approach that accounts for multilevel influences is necessary. This study is the second part (Aim 2) of a multi-component project and involves a patient- and clinic-level intervention in a public health family planning clinic in Duval County Florida, where most patients are women of color. The area has one of the highest HIV incidence rates among women in the US. The investigators developed 1) a tablet-based decision support tool (DST) that helps users learn about HIV vulnerabilities and HIV prevention strategies to inform how they consider options for reducing their likelihood of acquiring HIV, and 2) clinic-wide trainings regarding shared decision making and trauma informed care. In Aim 1 (previously completed), participants were randomized to viewing an HIV prevention DST in a clinic that had not received clinic-wide trainings. In Aim 2 (the present study), there will be two phases. In the first phase, participants will receive care at the clinic following training; the DST will not be used. In the second phase, in addition to being seen at a clinic-site that has experienced the training, participants will use the DST before their visit. Participants will be surveyed about experiences with HIV prevention counseling, intentions about using HIV prevention, and DST use (among those in the active arm in the second phase). A subset of participants, individuals who self-identify as Black or Latinx, will also complete a post-clinic visit interview. The investigators will assess whether participants initiated an HIV prevention method three months following their initial visit. The main outcomes will include a quantitative and qualitative assessment of PrEP or other HIV prevention use, decisional certainty, and satisfaction with information about HIV prevention options.

NCT ID: NCT05581160 Recruiting - Clinical trials for Chlamydia Trachomatis Infection

Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)

NGS-IST
Start date: July 11, 2022
Phase: N/A
Study type: Interventional

The main objective of the study will be to assess the performance of the Next-Generation-Sequencing (NGS) diagnostics of Chlamydia trachomatis and Neisseria gonorrhoeae compared to reference techniques.

NCT ID: NCT05564299 Recruiting - Clinical trials for Sexually Transmitted Infections

Rapid Diagnostic Assay for Gonorrhea and Chlamydia

Start date: March 22, 2023
Phase: N/A
Study type: Interventional

This study is a pilot randomized controlled trial evaluating the use of either a) rapid 30-minute desktop assay or b) point-of-care gram stain (current standard of care) to guide the clinical management of patients with symptomatic urethritis or cervicitis evaluated in the Massachusetts General Hospital Sexual Health Clinic. Patients presenting with symptoms of urethritis or cervicitis and meeting inclusion criteria will be randomized to have diagnostic specimens tested during the clinical encounter using either the 30-minute desktop assay or point-of-care gram stain. Patients randomized to the intervention arm of the study will also have a gram stain created, which will be held for interpretation by the clinician following the clinical encounter. Patients will not be followed longitudinally. Recruitment will conclude when 100 participants enroll in the study.

NCT ID: NCT05544851 Completed - Clinical trials for Sexually Transmitted Diseases

The Effect of Education Given to Reproductive Age Women by Teach Back Method on Behaviors

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

Sexually transmitted infections (STIs) are an important public health problem as they affect more than 1 million people worldwide every day. The extent of sexually transmitted diseases is still unknown due to underreporting, underdiagnosis or asymptomatic course of these diseases. When the literature is examined, it is seen that the incidence of STD has increased in recent years. The prevalence of premarital sexual intercourse as a result of the decrease in the age of sexual maturity but the increase in the age at marriage in general plays an important role in this increase. It is estimated that 46.8 million of 450 million people in the 15-49 age group living in the European region, including Turkey, have treatable STIs. STD can lead to many serious health problems such as infertility, ectopic pregnancy, cancer, chronic pelvic pain, pelvic adhesions and even death. Moreover, eye diseases, central nervous system infection and death may occur in the baby of an infected mother. In the report of the "Study on Sexual and Reproductive Health in Young People" conducted in Turkey in 2007, it was determined that young people do not have sufficient information about the reproductive organs, structure and physiology, health problems that may arise due to STD, HIV/AIDS, and ways of protection (6).An effective education; can significantly affect the quality of care, personal safety and satisfaction. One of the most effective and successful methods used in education is the Teach-Back method. Tell What You've Learned is a communication and education method used in health education for patients to remember and understand important information about diagnosis, treatment, medications or care. Tell What You've Learned is explained as a method that can be easily used for almost any interaction between healthcare team members and patients and can strengthen team understanding. It is recommended that all personnel, not only clinical caregivers, should use the method effectively in the health care system. It is stated that the conceptual framework of this method is based on the individuals receiving health services to present the information by arranging them according to themselves. It is considered as an effective method in terms of determining whether the transferred information is understood correctly. It is stated that 40-80% of the individuals who consult or immediately forget the information given to them about their health. Various factors that cause communication problems between healthcare professionals and clients during information transfer affect the clarity and permanence of the information given.The "Tell What You Have Learned" method is also expressed as closing the loop, and it is reported to be an effective method when used to eliminate the communication gap between healthcare professionals and service recipients. In addition, it is stated that the use of the method to control the materials (educational brochure, training guide, etc.) used by individuals leaving the hospital to access health information will have a positive effect on health outcomes. From another point of view; It is predicted that it will increase the health literacy rate, and it is accepted as a research-based health literacy intervention that enriches the communication between the health care provider and the service recipient, improves the health outcomes of the individual.

NCT ID: NCT05541081 Active, not recruiting - HIV Infections Clinical Trials

Investigating Point-of-care Diagnostics for Sexually Transmitted Infections and Antimicrobial Resistance in Primary Care in Zimbabwe

IPSAZ
Start date: January 12, 2023
Phase: N/A
Study type: Interventional

A prospective interventional study to evaluate a strategy of point-of-care testing for sexually transmitted infections including chlamydia, gonorrhoea, trichomoniasis, syphilis, and Hepatitis B with comprehensive case management including partner notification in antenatal settings in Harare province, Zimbabwe.

NCT ID: NCT05516069 Recruiting - HIV Clinical Trials

Our Healthbox - Evaluating Interactive Dispensing Systems for Low-Barrier Access to HIV Testing and Harm Reduction.

Start date: January 23, 2023
Phase: N/A
Study type: Interventional

When REACH Nexus at MAP Centre for Urban Solutions out of St. Michael's Hospital launched its signature program, I'm Ready in 2021, our goal was to democratize access to free HIV self-testing to reach the undiagnosed in Canada. The program, the first of its kind in Canada has been successfully rolling out 50,000 free, HIV self-tests and connecting participants via a mobile app on an iOS or Android smart phone to care. While this is an important milestone in improving access, REACH knows that more needs to be done. An estimated 20-30% of undiagnosed individuals do not have access to a phone to order the HIV self-tests, and many face multiple barriers to accessing healthcare and harm reduction support: chaotic life circumstances, addiction challenges, stigma and more. Everyone in Canada should have equitable access to the health care they need. But REACH knows that this is not the case.So, REACH is working hard to change this. hese ongoing barriers inspired us to continue creating innovative solutions, and launch our second signature program, Our Healthbox. Our Healthbox meets people where they are, with what they need for their health and well-being. This program is scaling up innovations in health technologies to reach undiagnosed individuals with HIV. These smart interactive vending machines will be strategically located across Canada. The goal is to reach people where they live to provide free and low barrier access to HIV self-testing kits, STBBI testing and other harm reduction supplies. Participation in Our Healthbox, as with I'm Ready, also gives us the opportunity to collect important data that will continue to inform and guide REACH Nexus' work to grow and scale innovative health solutions across the country.

NCT ID: NCT05504954 Completed - Hiv Clinical Trials

A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA

IMARA-SA pilot
Start date: October 26, 2019
Phase: N/A
Study type: Interventional

Programs which go beyond individual-level behavior change to reduce HIV and STI infections among adolescent girls and young women in sub-Saharan Africa are essential to meet global HIV targets. Informed, Motivated, Aware and Responsible Adolescents and Adults- South Africa (IMARA-SA) is an evidence-based HIV-prevention intervention for adolescent girls and young women (AGYW) and their female caregivers, which has been adapted for a South African audience. This pilot study will assess feasibility in preparation for a randomized controlled trial (RCT). Additionally, the pilot will examine the preliminary effectiveness of IMARA-SA in reducing sexually transmitted infections (STI) and increasing uptake of HIV testing and counseling (HTC) and pre-exposure prophylaxis (PrEP) at follow-up among AGYW. About 60 AGYW-FC dyads will be enrolled and randomized to IMARA-SA or a health-promotion control arm. Following randomization, the dyads will participate in an ~2-day group workshop (~10 hours), which includes joint and separate mother and daughter activities. AGYW and FC will complete baseline assessments and follow-up assessments approximately 6 months later. Assessments will include surveys, STIs testing (for chlamydia and gonorrhea), and uptake of HTC and a 1-month PrEP prescription. Additionally, the intervention's implementation (e.g., acceptability) will be explored.

NCT ID: NCT05492565 Enrolling by invitation - Clinical trials for Hepatitis, Viral, Human

Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis

SeVIHPrEP
Start date: January 1, 2020
Phase:
Study type: Observational [Patient Registry]

Pre-exposure prophylaxis (PrEP) based on tenofovir represents a considerably new preventive intervention that has shown to significantly decrease the number of HIV infections while it enables early diagnosis of HIV and other sexually transmitted diseases (STI). In Southern Spain, the target population to receive PrEP are men who have sex with men (MSM) with a history of STI and who pursue high-risk sexual practices regarding the acquisition of HIV, including an elevate number of sex partners, no or inconsistent condom use and the use of specific recreational drugs in the context of sexual activity ("chemsex"). Despite the benefits of PrEP use, it must be taken into consideration that risk compensations that may facilitate the acquisition of other STI may occur, including a higher implementation of risk practices and an increase in the number of partners, which is made easy as various social networks designed for this purpose are available nowadays. In order to better understand the benefit/drawback ratio, accurate data of a population using PrEP under real-life conditions, with densely scheduled follow-up and well-characterized (socio-)demographic parameters, sexual behaviour and STI are warranted.

NCT ID: NCT05463692 Enrolling by invitation - Hiv Clinical Trials

CAMELLIA Cohort: A Longitudinal Study to Understand Sexual Health and Prevention Among Women in Alabama

CAMELLIA
Start date: November 13, 2023
Phase: N/A
Study type: Interventional

Pre-exposure prophylaxis (PrEP) is an important biomedical human immunodeficiency virus (HIV) prevention tool and may particularly benefit black, cis and trans-gender women, who are at an increased risk for HIV and Sexually Transmitted Infections (STIs). The purpose of this study is to use a population-based approach to create a cohort of cis and trans-gender women at risk for future HIV acquisition to better understand the factors associated with the risk of STIs and HIV diagnosis and predictors of PrEP use.